PCMA Business Forum 2022

February 28
& March 1

JW Marriott Grande Lakes
Orlando, FL

PCMA Affiliate Sponsor: $2,445
Non-Member/Non-Affiliate: $3,195
Member: $0.00
Virtual Sessions-Only: $379

CPE ACTIVITY ANNOUNCEMENT

CPE Information

PCMA is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education (CPE). The 2022 PCMA Business Forum agenda currently includes 9 CPE-eligible sessions. Because some sessions are scheduled concurrently, individuals may obtain up to 3 total contact hours or 0.3 Continuing Education Units (CEUs) of education.

All sessions eligible for CPE credit are designated by CPE in the agenda.

Target Audience

All PCMA-offered CPE sessions are designed to be knowledge-based (K) activities for pharmacists (P). These sessions are designed to add to or enhance participants' knowledge of issues relevant to various pharmacists' career settings, including specialty pharmacy, and the business strategies that impact them.

PCMA-offered CPE sessions are designed to meet the educational needs of pharmacists from specialty pharmacies, PBMs, payer organizations, drug manufacturers, and numerous other specialty pharmacy stakeholders and service companies. Educational sessions are designed for those new to the business of specialty pharmacy, as well as for more season veterans.

Obtaining Credit

As of January 1, 2013 a system called the CPE Monitor, a joint collaboration between ACPE and NABP, became mandatory for all CPE providers and pharmacists to submit and receive CPE credit. The CPE Monitor allows providers to submit attendee lists online. The system communicates this information to NABP, which then communicates it to state boards of pharmacy electronically, removing the need for pharmacists to submit individual statements of credit.

In order to receive credit for attending accredited CPE offerings, you must have an e-profile ID number (e-PID) provided by NABP. If you have not yet obtained your NAPB e-PID, please do so by calling NABP customer service at 847.391.4406 or by emailing help@nabp.pharmacy.

At the conference: In order to obtain CEUs, please have your name badge scanned in each breakout session that you attend. A representative will be present in the back of each room to scan badges and answer any questions. Further questions can be directed to Brynn Hadley, bhadley@pcmanet.org.

After the conference: Be on the lookout for post-conference communications from PCMA. Depending on the session(s) you attended, it may be necessary for you to complete a learning assessment or evaluation before receiving credit.

PCMA will upload credit electronically to ACPE within (60) days of the conference. Credit should appear in your NABP account within a week of upload.

State Requirements: Some states have specific CPE requirements. Be sure to check with your state Board of Pharmacy to determine if such requirements exist and to determine if these programs meet those requirements.

Disclaimers

» PCMA plans all CPE-eligible sessions independently of commercial interests and PCMA does not accept grants to support any specific CPE programming.

» Educational content should be presented with full disclosure and equitable balance and should not include anything which is promotional, commercially biased, or which appears to endorse a drug, device or other commercial product or specific commercial service.

» The opinions expressed by speakers are those of the individual presenters. They do not necessarily reflect the views of PCMA or its members.

» CPE sessions may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Please refer to the official prescribing information for each product for information of approved indications, contraindications, and warnings.

AGENDA & SESSION DETAILS

Monday, February 28
10:30 am – 11:00 am

GENERAL SESSION

The Evolving Specialty Landscape: A Roadmap for the Future

Lucille Accetta, *Senior Vice President PBM, Specialty Product Development,* CVS Health

Jackie Mancini, *Vice President Formulary Strategy & Operations*, CVS Health

A robust pipeline, expanding indications, and more specialty treatments for conditions previously treated by “traditional” medications means utilization is increasing. Specialty medications now make up 54% of pharmacy spend. The evolving marketplace and complexity of treatment also means managing care for patients, while effectively controlling spend for payers continues to be challenging. The presenters will share perspective on what is impacting overall spend, how to provide comprehensive patient care and support, and considerations for new management strategies to help drive to lowest net cost for all.

By attending this session, you should be able to:

» Learn what is driving specialty spend and trend;

» Understand how technology and digital tools can help provide a comprehensive, seamless patient experience for those managing complex conditions;

» Hear about targeted approaches that can enhance management for specific therapeutic areas; and

» Learn about considerations for new approaches to delivering the lowest net cost for all in partnership with all stakeholders.

CPE

Activity Type: Knowledge-based (K)
Target Audience: Pharmacists (P)
CEUs: 0.050
UAN: 0841-0000-22-001-L04-P

Monday, February 28
1:30 pm – 2:00 pm

BREAKOUT SESSIONS (two concurrent)

PBM Clinical and Patient Care Programs: Aligning Pharmaceutical Care to Patients and Payers (Patient and Clinical Care Track)

Mark Bini, *Chief Patient Experience Officer*, Evernorth

Don’t miss learning how to harmonize care for patients, plans, and healthcare partners.

By attending this session, you should be able to:

» Describe the problem that healthcare fragmentation is causing for patients and plan sponsors;

» Understand the importance of interoperability across the healthcare ecosystem;

» Outline how Health Services Companies are putting into practice care coordination across pharmacy, medical and behavioral health; and

» Review the benefit of digital health solutions to patients.

CPE

Activity Type: Knowledge-based (K)
Target Audience: Pharmacists (P)
CEUs: 0.050
UAN: 0841-0000-22-002-L05-P

The Current State of the 340B Program (Specialty Track)

Jason Hardaway, *Managing Director*, CiiTA, Inc.

The 340B program is experiencing unprecedented legal and legislative changes. This session will briefly discuss these changes and explore their impact on the audience.

By attending this session, you should be able to:

» Describe the current regulatory and legal environment;

» Describes the 340B contract pharmacy

environment; and

- Outline three elements affecting growth of the total 340B sales.

CPE

Activity Type: Knowledge-based (K)
Target Audience: Pharmacists (P)
CEUs: 0.050
UAN: 0841-0000-22-003-L03-P

Monday, February 28
3:00 pm – 3:30 pm

Behavioral Moments: A Conversation about Behavioral Health and Pharmacy Innovation (Patient and Clinical Care Track)

Doug Nemecek, *Chief Medical Officer, Behavioral Health,* Evernorth

Melissa Reilly, *Chief Growth Officer, Behavioral Health,* Evernorth

Moderator: Jerry Miller, *President*, J Miller Consulting

Behavioral health is more talked about then ever but barriers in true integration between behavioral and pharmacy and whole person health still remain. Meaningful progress can be made by looking for behavioral health moments, opportunities to take the pulse on mental health status, as companies look to leverage innovation and new care pathways.

By attending this session, you should be able to:

- Be conversant about the value of behavioral health in the pharmacy space;
- Understand recent market trends and innovations inclusive of digital therapeutics, specialty pharmacy and pharmacogenomics; and
- Discuss how to find or create Behavioral health moments when individuals are seeking quality care.

CPE

Activity Type: Knowledge-based (K)
Target Audience: Pharmacists (P)
CEUs: 0.050
UAN: 0841-0000-22-004-L04-P

Tuesday, March 1
11:30 am – 12:00 pm

GENERAL SESSION

Current and Future Trends in Specialty Pharmaceuticals

Doug Long, *Vice President, Industry Relations,* IQVIA

The COVID-19 pandemic has been a significant disruptor to patient care across the health care system. Patient visits with physicians declined, prescription drug prescribing and utilization were significantly impacted, and a new “normal” has emerged. Doug Long will break down the data to highlight the pandemic’s impact on Specialty pharmaceutical care and discuss what the new normal may look like.

By attending this session, you should be able to:

- recognize where the US Specialty Pharmaceutical market growth has been and near-term forecast for growth;
- identify the fastest growing Specialty classes and products and the slowest growing;
- understand new and future launches; and
- identify which factors will affect future growth.

CPE

Activity Type: Knowledge-based (K)
Target Audience: Pharmacists (P)
CEUs: 0.050
UAN: 0841-0000-22-005-L04-P

Tuesday, March 1
2:00 pm – 2:30 pm

BREAKOUT SESSIONS (two concurrent)

Physician Engagement in the Integrated Care Model (Patient and Clinical Care Track)

Ann Nguyen, *Vice President, Enterprise Pharmacy,* OptumCare

As health care continues to evolve, coupled with an unprecedented demand for services and transformative delivery models, physicians, pharmacists, and healthcare professionals are re(engineering) the care team approach and ecosystem. This session will explore the growing trend for integrated team-based care models to drive coordinated treatment planning, whole patient care management, and how this may reshape the interactions with pharmaceutical manufacturers.

By attending this session, you should be able to:

» Recognize the different provider payment risk models and how this can change the “payor” landscape;

» Explore an integrated care model ecosystem aimed at reshaping physician and pharmacist engagement to achieve better patient outcomes and value; and

» Identify emerging trends that pharmaceutical companies, health plans, and PBMs can impact to reshape health care or prescription transactions.

CPE

Activity Type: Knowledge-based (K)
Target Audience: Pharmacists (P)
CEUs: 0.050
UAN: 0841-0000-22-007-L04-P

The Emerging US Biosimilars Marketplace — Past, Present, and Future (Specialty Track)

Jon Martin, *Associate Vice President, US Biosimilars,* Organon

Emily Colaizy, *Assistant Vice President, Trade Relations and Strategy*, Prime Therapeutics

The US biosimilars market has largely been focused on medical benefit therapies, but the pharmacy benefit biosimilar market will see rapid growth in the coming years. Emily and Jon will discuss past, present and future adoption, compare the US market evolution with the EU experience, and discuss key considerations for the future.

By attending this session, you should be able to:

» Recognize past and current US biosimilar adoption rates;

» Describe the pipeline of future biosimilar introductions; and

» Understand the ways US payers may optimize biosimilar education and uptake.

CPE

Activity Type: Knowledge-based (K)
Target Audience: Pharmacists (P)
CEUs: 0.050
UAN: 0841-0000-22-006-L04-P

Tuesday, March 1
2:45 pm – 3:15 pm

BREAKOUT SESSIONS (two concurrent)

Drug Development Pipeline: Innovation, Patient Care, and Cost Management (Patient and Clinical Care Track)

Linda Isham, *Vice President, Clinical Strategies and Operations,* Humana

Over the past five years, there have been an increasing number of novel drugs that have been approved by the FDA with 59 new drugs being approved in 2021. Linda Isham will discuss how PBMs are tracking the clinical pipeline and the information that is necessary to support P&T Committee decision making.

By attending this session, you should be able to:

» Understand trends on novel drug approvals and disease states;

» Discuss practices used by PBMs to monitor the drug development pipeline; and

» Identify opportunities to enhance components of the drug development pipeline to support P&T decisions.

CPE

Activity Type: Knowledge-based (K)
Target Audience: Pharmacists (P)
CEUs: 0.050
UAN: 0841-0000-22-009-L04-P

Introduction to Self-Funded Medical Plans: Why Employer Groups Could Be Financing High Cost Therapies (Specialty Track)

Matt Paul, *Senior Vice President, Value and Access,* COEUS Consulting

A substantial portion of employee’s in the commercial market are on a self funded platform for their employer sponsored health plan. High cost Rx / therapies are compromising the integrity of the employee’s claim fund, forcing employer’s & carrier’s to shift liability. Matt Paul will highlight the basics of a self funded plan and the thought process around why this is occurring.

By attending this session, you should be able to:

» Understand why groups choose to self fund their employee medical plan;

» List what types of groups self fund;

» Describe the size of the commercial market on a self funded platform;

» Identify the reason for purchasing stop loss insurance;

» List the reason for lasering; and

» Identify why groups are carving Specialty Rx / infusion therapies out of the plan.

CPE

Activity Type: Knowledge-based (K)
Target Audience: Pharmacists (P)
CEUs: 0.050
UAN: 0841-0000-22-008-L04-P